Initial Solvent Screening of Carbamazepine, Cimetidine, and Phenylbutazone Part 1 of 2

Pharmaceutical Technology

Volumn 33, Issue 5, 2009, Pages 62-72

  Lee, Tu ^a   Su, Yan Chan ^a   Hou, Hung Ju ^a   Hsieh, Hsiang Yu ^a  

^a NATIONAL CENTRAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; CARBAMAZEPINE; COMPOSITION RATIO; CRYSTAL HABITS; ORGANIC NANOCRYSTALS; SCINTILLATION VIALS; SCREENING STRATEGY; SPHERICAL CRYSTALLIZATION;

AMIDES; MICROEMULSIONS;

SOLVENTS;

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NANOCRYSTAL; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; SOLVENT;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; CRYSTAL; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STRUCTURE; EPILEPSY; FOURIER TRANSFORMATION; INFRARED SPECTROSCOPY; MICROEMULSION; MICROSCOPY; PAIN; PEPTIC ULCER; POWDER; SCANNING ELECTRON MICROSCOPY; SCINTILLATION; SCREENING; SOLID STATE; TRIGEMINUS NEURALGIA; X RAY DIFFRACTION; X RAY POWDER DIFFRACTION;

EID: 67650092769     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Y. Kawashima and C.E. Capes, "An Experimental Study of the Kinetics of Spherical Agglomeration in a Stirred Vessel," Powder Technol. 10 (1-2), 85-92 (1974).
2. Y. Kawashima and C.E. Capes, "Further Studies of the Kinetics of Spherical Agglomeration in a Stirred Vessel," Powder Technol. 13 (2), 279-288 (1976).
3. Y. Kawashima, M.Okumura, and H. Takenaka, "Spherical Crystallization: Direct Spherical Agglomeration of Salicylic Acid Crystals During Crystallization," Science 216 (4550), 1127-1128 (1982).
4. Y. Kawashima et al., "Preparation of Spherically Agglomerated Crystals of Aminophylline," J. Pharm. Sci. 73 (10), 1407-1409 (1984).
5. Y. Kawashima, M. Okumura, and H. Takenaka, "The Effects of Temperature on the Spherical Crystallization of Salicylic Acid," Powder Technol. 39 (1), 41-47 (1984).
6. Y. Kawashima et al., "Preparations of Agglomerated Crystals of Polymorphic Mixtures and a New Complex of Indomethacin-Epirizolehy the Spherical Crystallization Technique," J. Pharm. Sci. 74 (11), 1152-1156 (1985).
7. A. Sano et al., "Particle Design of Tolbutamide by the Spherical Crystallization Technique II: Factors Causing Polymorphism of Tolbutamide Spherical Agglomerates," Chem. Pharm. Bull. 37 (8), 2183-2187 (1989).
8. Y. Kawashima et al., "Characterization of Polymorphs of Tranilast Anhydrate and Tranilast Monohydrate When Crystallized by Two Solvent Change Spherical Crystallization Techniques," J. Pharm. Sci. 80 (5), 472-478 (1991).
9. K. Morishima et al., "Micromeritic Characteristics and Agglomeration Mechanisms in the Spherical Crystallization of Bucillamine by the Spherical Agglomeration and the Emulsion Solvent Diffusion Methods," Powder Technol. 76 (1), 57-64 (1993).
10. Y Kawashima et aL, "Improvements in Flowability and Compressibility of Pharmaceutical Crystals for Direct Tabletting by Spherical Crystallization with a Two-Solvent System," Powder Technol. 78 (2), 151-157 (1994).
11. K. Morishima et al., "Tabletting Properties of Bucillamine Agglomerates Prepared by the Spherical Crystallization Technique," Int. J. Pharm. 105 (11), 11-18 (1994).
12. A.M. Garcia and E.S. Ghaly, "Preliminary Spherical Agglomerates of Water Soluble Drug Using Natural Polymer and Cross-Linking Technique,"J. Control. Release 40 (3), 179-186 (1996).
13. A.H.L. Chow and M.W.M. Leung, "A Study of the Mechanisms of Wet Spherical Agglomeration of Pharmaceutical Powders," DrugDev. Ind. Pharm. 22 (4), 357-371 (1996).
14. U. Teipel, T. Heintz, and H.H. Krause, "Crystallization of Spherical Ammonium Dinitramide (ADN) Particles," Propellants, Explosives, Pyrotechnics 25 (2), 81-85 (2000).
15. P. Szabó-Révész et al., "Development of Spherical Crystal Agglomerates of an Aspartic Acid Salt for Direct Tablet Making," Powder Technol. 114 (1), 118-124 (2001).
16. A.R. Paradkar et al., "Spherical Crystallization of Celecoxib," DrugDev. Ind. Pharm. 28 (10), 1213-1220 (2002).
17. P. Szabó-Révész et al., "Crystal Growth of Drug Materials by Spherical Crystallization," J. Cryst. Growth 237-239 (part 3), 2240-2245(2002).
18. Y. Kawashima et al., "Improved Flowability and Compactibility of Spherically Agglomerated Crystals of Ascorbic Acid for Direct Tableting Designed by Spherical Crystallization Process," Powder Technol. 130(1), 283-289 (2003).
19. A.P. Pawar et aL, "Crystallo-co-agglomeration: A Novel Technique to Obtain Ibuprofen-Paracetamol Agglomerates," AAPS Pharm. Sci. Tech., 5 (3), Article 44 (2004).
20. S. Bhadra et al., "Spherical Crystallization of Mefenamic Acid," Pharm. Technol. 28 (2), 66-76 (2004).
21. M. Maghsoodi et al., "Improved Compaction and Packing Properties of Naproxen Agglomerated Crystals Obtained by Spherical Crystallization Technique " DrugDev. Ind. Pharm. 33 (11), 1216-1224 (2007).
22. J. Katta and Å.C. Rasmuson, "Spherical Crystallization of Benzoic Acid," Int. J. Pharm. 348 (1-2), 61-69 (2008).
23. X. Iiu et al., "Single-Crystal-like Materials by the Self-Assembly of Cube-Shaped Lead Zirconate Titanate (PZT) Microcrystals," Langmuir 21 (8), 3207-3212(2005).
24. A.S. Utada et aL, "Monodisperse Double Emulsions Generated from a Microcapillary Device," Science 308 (5721), 537-541 (2005).
25. S. Gupta and S.P. Moulik, "Biocompatible Microemulsions and Their Prospective Uses in Drug Delivery," J. Pharm. Sci. 97 (1), 22-15 (2008).
26. K. Ujiiye-Ishii et al., "Methodological Features of the Emulsion and Reprecipitation Methods for Organic Nanocrystal Fabrication," Cryst. Growth Des. 8 (2), 369-371 (2008).
27. T. Lee and S.T. Hung, "Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs," Pharm. Technol. 32 (1), 76-95 (2008).
28. T. Lee, C.S. Kuo, and Y.H. Chen, "Solubility, Polymorphism, Crystallinity, and Crystal Habit of Acetaminophen and Ibuprofen," Pharm. Technol. 30 (10), 72-92 (2006).
29. T. Lee, Y.H. Chen, and C.W. Zhang, "Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R,S)-(±)- Sodium Ibuprofen Dihydrate," Pharm. Technol. 31 (6), 72-87 (2007).
30. T. Lee and M.S. Lin, "Sublimation Point Depression of Tris(8- hydroxyquinoline)aluminum(III) (Alq3) by Crystal Engineering," Cryst. Growth Des. 7 (9), 1803-1810 (2007).
31. J. Alsenz and M. Kansy, "High Throughput Solubility Measurement in Drug Discovery and Development," Adv. Drug Deliv. Rev. 59 (7), 546-567 (2007).
32. T. Umeda et al., "Kinetics of the Thermal Transition of Carbamazepine Polymorphic Forms in the Solid State," Yakugaku Zasshi 104 (7), 786-792 (1984).
33. M.M.J. Lowes et al., "Physicochemical Properties and X-ray Structural Studies of the Trigonal Polymorph of Carbamazepine," J. Pharm. Sci. 76 (9), 744-752 (1987).
34. F.U. Krahn and J.B. Mielck, "Relations between Several Polymorphic Forms and the Dihydrate of Carbamazepine," Pharm. Acta Helv. 62 (9), 247-254 (1987).
35. J. Dugue et al., "Polymorphism of Carbamazepine: Solid-State Studies on Carbamazepine Dihydrate," Pharm. Acta Helv. 66 (11), 307-310 (1991).
36. L.E. McMahon et al., "Characterization of Dihydrates Prepared from Carbamazepine Polymorphs," J. Pharm. Sci. 85 (10), 1064-1069 (1996).
37. I. Katzhendler, R. Azoury, and M. Friedman, "Crystalline Properties of Carbamazepine in Sustained Release Hydrophilic Matrix Tablets Based on Hydroxypropyl Methylcellulose," J. Control. Release 54 (1), 69-85 (1998).
38. Y. Kobayashi et al., "Physicochemical Properties and Bioavailability of Carbamazepine Polymorphs and Dihydrate," Int. J. Pharm. 193 (2), 137-146 (2000).
39. C. Rustichelli et al., "Solid-State Study of Polymorphic Drugs: Carbamazepine,"J. Pharm. Biomed. Anal. 23 (1), 41-54 (2000).
40. R. Nair, S. Gonen, and S.W. Hoag, "Influence of Polyethylene Glycol and Povidone on the Polymorphic Transformation and Solubility of Carbamazepine," Int. J. Pharm. 240 (1-2), 11-22 (2002).
41. Y Yoshihashi, E. Yonemochi, and K. Terada, "Estimation of Initial Dissolution Rate of Drug Substance by Thermal Analysis: Application for Carbamazepine Hydrate," Pharm. Dev. Technol. 7 (1), 89-95 (2002).
42. A. Cvetkovskii et al., "Thermal Properties of Binary Mixtures of b̃-Cyclodextrin with Carbamazepine Polymorphs," J. Therm. Anal. Calorim. 68 (2), 669-678 (2002).
43. A. L. Grzesiak et al., "Comparison of the Four Anhydrous Polymorphs of Carbamazepine and the Crystal Structure of Form I," J. Pharm. Sci. 92 (11), 2260-2271 (2003).
44. R. Hilfiker et al., "Polymorphism-Integrated Approach from High-Throughput Screening to Crystallization Optimization," J. Therm. Anal. Calorim. 73 (2) 429-440 (2003).
45. S.G. Fleischman et al., "Crystal Engineering of the Composition of Pharmaceutical Phases: Multiple-Component Crystalline Solids Involving Carbamazepine," Cryst. Growth Des. 3 (6), 909-919 (2003).
46. N. Rodríguez-Hornedo and D. Murphy, "Surfactant-Facilitated Crystallization of Dihydrate Carbamazepine during Dissolution of Anhydrous Polymorph," J. Pharm. Sci. 93 (2), 449-460 (2004).
47. H.G. Brittain, "Fluorescence Studies of the Transformation of Carbamazepine Anhydrate Form III to Its Dihydrate Phase," J. Pharm. Sci. 93 (2), 375-383 (2004).
48. C. McGregor et al., "The Use of High-Speed Differential Scanning Calorimetry (Hyper-DSC) to Study the Thermal Properties of Carbamazepine Polymorphs," Thermochimica Acta 417 (2), 231-237 (2004).
49. A.J. Cruz Cabeza et al., "Importance of Molecular Shape for the Overall Stability of Hydrogen Bond Motifs in the Crystal Structures of Various Carbamazepine-Type Drug Molecules," Cryst. Growth Des. 7 (1), 100-107 (2007).
50. K. Seefeldt et al., "Crystallization Pathways and Kinetics of Carbamazepine-Nicotinamide Cocrystals from the Amorphous State by In Situ Thermomicroscopy, Spectroscopy, and Calorimetry Studies," J. Pharm. Sci. 96 (5) 1147-1158 (2007).
51. F. Tian et al., "Influence of Polymorphic Form, Morphology, and Excipient Interactions on the Disoolution of Carbamazepine Compacts,"J. Pharm. Sci. 96 (3), 584-594 (2007).
52. M. Shibata et al., "X-Ray Structural Studies and Physicochemical Properties of Cimetidine Polymorphism," J. Pharm. Sci. 72 (12), 1436-1442 (1983).
53. B. Hegediis and S. Gorog, "The Polymorphism of Cimetidine," J. Pharm. Biomed. Anal. 3 (4), 303-313 (1985).
54. S. Sudo, K. Sato, and Y. Harano, "Solubilities and Crystallization Behavior of Cimetidine Polymorphic Forms A and B," J. Chem. Eng. Japan 24 (2), 237-242 (1991).
55. A. M. Tudor et al., "The Applications of Near-Infrared Fourier Transform Raman Spectroscopy to the Analysis of Polymorphic Forms of Cimetidine," Spectrochim. Acta 47A (9/10), 1389-1393 (1991).
56. E. Hadicke, F. Frickel, and A. Franke, "Die Strukturvon Cimetidin (N"- Cyan-N-Methyl-N'-[2-[(5-methyl-lH-imidazol-4-yl)methylthio] ethyl]guanidine), einem Histamin H2-Rezeptor-Antagonist," Chem. Ber. 111 (9), 3222-3232 (1978).
57. A. Bauer-Brandl, "Polymorphic Transitions of Cimetidine during Manufacture of Solid Dosage Forms," Int. J. Pharm. 140 (2), 195-206 (1996).
58. A. Bauer-Brandl et al., "Comparison of Experimental Methods and Theoretical Calculations on Crystal Energies of 'Isoenergetic' Polymorphs of Cimetidine," J. Therm. Anal. Calorim. 57 (1), 7-22 (1999).
59. W. A. Bueno and E.G. Sobrinho, "Hydrogen Bonds in the Cimetidine Molecule," Spectrochim. Acta 51A (2), 287-292 (1995).
60. H.G. Ibrahim, F. Pisano, and A. Bruno, "Polymorphism of Phenylbutazone: Properties and Compressional Behavior of Crystals," J. Pharm. Sci. 66 (5) 669-673 (1977).
61. Y Matsuda et al., "Polymorphism of Phenylbutazone by a Spray Drying Method," J. Pharm. Pharmacol. 32 (8), 579-580 (1980).
62. M.D. Tuladhar, J.E. Carless, and M.P. Summers, "Thermal Behavior and Dissolution Properties of Phenylbutazone Polymorphs," J. Pharm. Pharmacol. 35 (4), 208-214 (1983).
63. Y Matsuda et al., "Physiochemical Characterization of Spray-Dried Phenylbutazone Polymorphs,"J. Pharm. Sci. 73 (2), 173-179 (1984).
64. H.H. Paradies, "Structure of Phenylbutazone and Mofebutazone in the Crystalline State and in Solution," J. Pharm. Sci. 76 (12), 920-929 (1987).
65. T. Matsumoto et al., "Effect of Environmental Temperature on the Polymorphic Transformation of Phenylbutazone during Grinding," Chem. Pharm. Bull. 36 (3), 1074-1085 (1988).
66. N. Kaneniwa, J.I. Ichikawa, and T. Matsumoto, "Preparation of Phenylbutazone Polymorphs and Their Transformation in Solution," Chem. Pharm. Bull. 36 (3), 1063-1073 (1988).
67. A. Beretzky et al., "Pelletization of Needle-Shaped Phenylbutazone crystals," J. Therm. Anal. Calorim. 69 (2), 529-539 (2002).
68. T. Hosokawa et al., "Isostructurality among Five Solvates of Phenylbutazone," Cryst. Growth Des. 4 (6), 1195-1201 (2004).
69. T. Hosokawa et al, "Relationships between Crystal Structures and Thermodynamic Properties of Phenylbutazone Solvates," Cryst. Eng. Comm. 6 (44), 243-249 (2004).
70. N.G. Anderson, "Solvent Selection," in Practical Process Research and Development (Academic Press, New York, 1st ed, 2000), pp. 81-111. PT